heat.

@heatinformatics

Health Evaluations & Applied Therapeutics | News & Intelligence on BioPharmaceutical Pricing & Access. Content curated by

Toronto, ON CANADA
Vrijeme pridruživanja: studeni 2013.

Tweetovi

Blokirali ste korisnika/cu @heatinformatics

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @heatinformatics

  1. 23. sij

    The industry has been spouting dire warnings about what will happen if governments try to regulate medication prices. Well here’s what happened when Germany ignored those warnings |

    Poništi
  2. 23. sij
    Poništi
  3. 23. sij

    UK's NICE has rejected a number of drugs from coverage recently based on cost-effectiveness criteria |

    Poništi
  4. 17. sij

    Drugmakers are girding for more pain as China embarks on its biggest round of price cuts yet to reduce health costs in the world’s second-largest market. The extent of the price cuts this time could range from 20% to more than 50% |

    Poništi
  5. 17. sij

    Will EU health systems, particularly those with established processes for determining cost-effectiveness, be able to adapt their models to look beyond the immediate upfront costs and take into account longer-term savings associated with gene therapies? |

    Poništi
  6. 17. sij

    CEOs from the world’s largest companies pitched ideas for lowering drug prices - none, however, offered to cut the prices of their own drugs |

    Poništi
  7. 17. sij

    40 million people with diabetes globally will be left without insulin by 2030 |

    Poništi
  8. 17. sij

    With a list price of $225,000 per year, tafamidis is the most expensive cardiovascular drug on the market |

    Poništi
  9. 17. sij

    BioMarin is exploring pricing its experimental gene therapy for hemophilia patients - Valrox - between $2 million and $3 million if it is approved |

    Poništi
  10. 15. sij

    Eli Lilly and Co plans to sell two versions of insulin products at half their current U.S. list prices |

    Poništi
  11. 15. sij

    Third-to-market plans to aggressively challenge pricing of two of the world’s most expensive medicines |

    Poništi
  12. 13. sij
    Poništi
  13. 13. sij

    From instalment-plans to subscriptions to more complex value-based contracts, companies are tinkering with how they get paid |

    Poništi
  14. 10. sij
    Poništi
  15. 10. sij

    California could become the first American state to sell its own brand of generic prescription drugs in an effort to drive down rising healthcare costs |

    Poništi
  16. 10. sij

    New product treating rare form of cancer that affects the stomach and small intestine priced at a wholesale acquisition cost (list price) of $32,000 for a 30-day supply, regardless of dosage |

    Poništi
  17. 9. sij
    Poništi
  18. 9. sij

    If Americans were to match the average prices of prescription medications in the UK, Canada, and Japan, there would be a 70% drop in drug spending. Holy economic opportunity! |

    Poništi
  19. 9. sij

    Even when nearly everyone in Washington wants to lower drug prices, it takes years to get anything done |

    Poništi
  20. 9. sij

    Chile's President Sebastian Pinera has enacted a law to cut the price of drugs by up to 80 percent. The initiative will take effect on April 6th |

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·